Unknown

Dataset Information

0

Lower risk but high risk.


ABSTRACT: Risk stratification is crucial to the appropriate management of most cancers, but in patients with myelodysplastic syndromes (MDS), for whom expected survival can vary from a few months to more than a decade, accurate disease prognostication is especially important. Currently, patients with MDS are often grouped into higher-risk (HR) vs lower-risk (LR) disease using clinical prognostic scoring systems, but these systems have limitations. Factors such as molecular genetic information or disease characteristics not captured in the International Prognostic Scoring System-Revised (IPSS-R) can alter risk stratification and identify a subset of patients with LR-MDS who actually behave more like those with HR-MDS. This review describes the current identification and management of patients with LR-MDS whose condition is likely to behave in a less favorable manner than predicted by the IPSS-R.

SUBMITTER: DeZern AE 

PROVIDER: S-EPMC8791100 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6533753 | biostudies-literature
| S-EPMC7902818 | biostudies-literature
| S-EPMC7096386 | biostudies-literature
| S-EPMC7296269 | biostudies-literature
2007-08-01 | GSE5576 | GEO
| PRJEB66515 | ENA
| S-EPMC3962994 | biostudies-literature
| S-EPMC9821551 | biostudies-literature
| S-EPMC6031056 | biostudies-literature
| S-EPMC6347124 | biostudies-literature